Lv2
180 积分 2022-09-27 加入
Targeting the phosphoinositide 3-kinase pathway in cancer
21天前
已完结
Benzothiophene-based, orally active PIK3CA H1047R mutant-selective inhibitors for the treatment of HR+/HER2- breast cancer
27天前
已完结
Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity
1个月前
已完结
Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates
1个月前
已完结
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
7个月前
已完结
Generative AI: a generation-defining shift for biopharma regulatory affairs
7个月前
已完结
Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy
7个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
11个月前
已完结
Optimizing the FDA’s Project Optimus: opportunities and challenges
11个月前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
11个月前
已完结
皖公网安备34019202002308
